Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 25;47(2):e24245. doi: 10.1002/clc.24245

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

(A) The event‐free survival for patients treated with ERA+Rio+Sel and ERA+PDE5i+Sel. (B) The all‐cause survival for patients treated with ERA+Rio+Sel and ERA+PDE5i+Sel. (C) The event‐free survival for patients treated with Amb+Rio+Sel and Mac+Rio+Sel. (D) The all‐cause survival for patients treated with Amb+Rio+Sel and Mac+Rio+Sel. (E) The event‐free survival for patients treated with Amb+Sil+Sel, Amb+Tad+Sel, Mac+Sil+Sel, and Mac+Tad+Sel. (F) The all‐cause survival for patients treated with Amb+Sil+Sel, Amb+Tad+Sel, Mac+Sil+Sel, and Mac+Tad+Sel. Amb, ambrisentan; ERA, endothelin receptor antagonist; Mac, macitentan; PDE5i, phosphodiesterase 5 inhibitor; Rio, riociguat; Sel, selexipag; Sil, sildenafil; Tad, tadalafil.